TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15969892

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 14513648

Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg subcutaneously daily for 7 days starting on day 21 of menstrual cycle
Number of subjects: 120

Group type: COMPARATOR
Intervention: Buserelin intranasal spray (long protocol)
Number of subjects: 120
Study: 10371363

Group type: EXPERIMENTAL
Intervention: Nurse-community health worker team in combination with usual medical care (SI)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual medical care (UC) alone
Number of subjects: 204
Study: 11324828

Group type: EXPERIMENTAL
Intervention: NASBA assay
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amplicor assay
Number of subjects: 24
Study: 1960249

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing varnish
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 51

Group type: COMPARATOR
Intervention: Prophylaxis alone
Number of subjects: 51
Study: 6816316

Group type: EXPERIMENTAL
Intervention: Combination of endocrine and chemical therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 30712804

Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 0
Study: 28686808

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Oral Health Promotion intervention (two 15-minute skills-based educational modules)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard CenteringPregnancy prenatal care
Number of subjects: 101
Study: 26668436

Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (mHealth) comprising six automated, interactive voice messages with counsellor phone support.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 500
Study: 23823584

Group type: EXPERIMENTAL
Intervention: Micronutrients with sugar
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Micronutrients with non-nutritive sweetener
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Sugar with micronutrients
Number of subjects: 414

Group type: COMPARATOR
Intervention: Micronutrients alone
Number of subjects: 414

Group type: COMPARATOR
Intervention: Sugar alone
Number of subjects: 414
Study: 21130446

Group type: EXPERIMENTAL
Intervention: 400‐μg sublingual misoprostol plus routine uterotonics
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Routine uterotonics
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: 400‐μg sublingual misoprostol
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1345
Study: 19897985

Group type: EXPERIMENTAL
Intervention: Antegrade intramedullary nail
Number of subjects: 70

Group type: COMPARATOR
Intervention: Retrograde intramedullary nail
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Isokinetic evaluation
Number of subjects: 70
Study: 17522509

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 315
Study: 15241630

Group type: EXPERIMENTAL
Intervention: ECD registration with count difference (CD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ECD registration with normalized mutual information (NMI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TCT registration with count difference (CD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TCT registration with normalized mutual information (NMI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TCT registration with NMI
Number of subjects: 25
Study: 11589872

Group type: EXPERIMENTAL
Intervention: Laser-assisted in situ keratomileusis (LASIK)
Number of subjects: 20
Study: 9834799

Group type: EXPERIMENTAL
Intervention: DBS (double burst stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CC (clinical criteria)
Number of subjects: 60
Study: 7857516

Group type: EXPERIMENTAL
Intervention: 3 x 300 mg hypericum extract
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 799996

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate (1, 2, and 4 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pentazocine lactate (30 and 60 mg)
Number of subjects: 124
Study: 31644514

Group type: EXPERIMENTAL
Intervention: Tritube with flow-controlled ventilation (FCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microlaryngeal tube (MLT) with volume-controlled ventilation (VCV)
Number of subjects: 40
Study: 28704733

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (potentiation protocol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation combined with a depotentiation protocol (short continuous theta-burst stimulation)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 25964369

Group type: EXPERIMENTAL
Intervention: Curriculum
Number of subjects: 5440

Group type: EXPERIMENTAL
Intervention: Mandatory daily hand washing before lunch
Number of subjects: 5440

Group type: EXPERIMENTAL
Intervention: Extra cleaning of school toilets
Number of subjects: 5440

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5440
Study: 23529779

Group type: EXPERIMENTAL
Intervention: Robotic thyroidectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional open thyroidectomy
Number of subjects: 90
Study: 22282730

Group type: EXPERIMENTAL
Intervention: Immediate implant placement (54 patients)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Delayed placement (52 patients)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 18668226

Group type: EXPERIMENTAL
Intervention: lorazepam 0.5 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: lorazepam 1.0 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 17042845

Group type: EXPERIMENTAL
Intervention: Study lecture with images of a train set delivering rocks (analogy to oxygen delivery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control lecture (oxygen delivery and hypoxaemia)
Number of subjects: 0
Study: 14581110

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion for 90 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-administration of S-ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 10969200

Group type: EXPERIMENTAL
Intervention: Distance measures computed from PCA of EMG waveforms during trunk movements
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Reliability analysis of distance measures
Number of subjects: 33
Study: 9102590

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium, 2500 IU
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nadroparin calcium, 3075 IU
Number of subjects: 30
Study: 1615227

Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 45 Torr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 50 Torr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 55 Torr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 65 Torr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: End-tidal PO2 at 75 Torr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Relief of hypoxia
Number of subjects: 6
Study: 6486249

Group type: EXPERIMENTAL
Intervention: Counseling plus cognitive‐behavioral psychotherapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Counseling plus supportive‐expressive psychotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Paraprofessional drug counseling alone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 110
Study: 31328399

Group type: EXPERIMENTAL
Intervention: Unconditional monetary incentive (£5 gift voucher with questionnaires)
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Conditional monetary incentive (£5 gift voucher promised after returning questionnaires)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Unconditional monetary incentive
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Conditional monetary incentive
Number of subjects: 1079
Study: 31030876

Group type: EXPERIMENTAL
Intervention: Increased avoidance behavior and unhelpful gastrointestinal (GI) cognitions
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Increased control behaviors
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral differences across Rome III classified IBS subtypes
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 557

Group type: COMPARATOR
Intervention: No differences in anxiety, depression, overall symptom severity, or work and social adjustment
Number of subjects: 557
Study: 27981431

Group type: EXPERIMENTAL
Intervention: enzalutamide 160 mg/day
Number of subjects: 1717

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1717
Study: 25720808

Group type: EXPERIMENTAL
Intervention: Marbofloxacin (2 mg/kg, IV, once; MRFX group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (saline solution 0.9% NaCl, 10 ml, IV, once)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Marbofloxacin (2 mg/kg, IV, once; MRFX group) and Enrofloxacin (5 mg/kg, IV, once; ERFX group)
Number of subjects: 48
Study: 24381153

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall anticoagulation preference tool
Number of subjects: 180
Study: 22459559

Group type: EXPERIMENTAL
Intervention: Enactment condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual condition
Number of subjects: 0
Study: 19873912

Group type: EXPERIMENTAL
Intervention: Linggui Bafa acupuncture treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no acupuncture or oral medication)
Number of subjects: 120
Study: 17398061

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15304576

Group type: EXPERIMENTAL
Intervention: Body temperature >37.5 degrees C
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Neutrophil count (by 1,000-unit increase)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Serum fibrinogen levels >523 mg/dL
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Early ICH growth
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Intraventricular bleeding
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Highest systolic blood pressure (by 10-unit increase)
Number of subjects: 266
Study: 11210398

Group type: COMPARATOR
Intervention: Fasting state (no food)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 15
Study: 9762782

Group type: EXPERIMENTAL
Intervention: Formoterol 72 microg (4+4+4 doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Terbutaline 6 mg (4+4+4 doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formoterol 120 microg (8+6+6 doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Terbutaline 10 mg (8+6+6 doses)
Number of subjects: 27
Study: 7531054

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) instruments analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three possible approaches to the analysis of QOL data
Number of subjects: 0
Study: 2894490

Group type: EXPERIMENTAL
Intervention: Intravenous APSAC (30 unit dose)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study: 30068306

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen sponge with systemic antibiotic therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Systemic antibiotics alone (Control)
Number of subjects: 88
Study: 26825817

Group type: EXPERIMENTAL
Intervention: Intravenous fluids (IVF)
Number of subjects: 570

Group type: COMPARATOR
Intervention: No intravenous fluids (IVF)
Number of subjects: 570
Study: 25298250

Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Stenting with perforation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Unperforated stenting
Number of subjects: 58
Study: 23711810

Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Angiographically guided DES implantation
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation in patients with diabetes mellitus
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Angiographically guided DES implantation in patients with diabetes mellitus
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: IVUS-guided DES implantation in patients with acute coronary syndrome
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Angiographically guided DES implantation in patients with acute coronary syndrome
Number of subjects: 1574
Study: 19925497

Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole 40 mg suspension o.m. for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delayed-release omeprazole 40 mg capsule o.m. for 7 days
Number of subjects: 12
Study: 17917501

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg plus amlodipine 5 mg
Number of subjects: 545

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 545
Study: 15476129

Group type: EXPERIMENTAL
Intervention: Positioning (four different positions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mother's milk or preterm formula (prior to positioning)
Number of subjects: 8
Study: 11308066

Group type: EXPERIMENTAL
Intervention: Rheumatologist visit in the last 12 months
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: General practitioner visit in the last 12 months
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Low involvement score
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: High education level and health service provided by rheumatologists
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Good mental health and high involvement
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Low pain level and good mental health
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Low score on involvement
Number of subjects: 2533
Study: 9602577

Group type: EXPERIMENTAL
Intervention: Ondansetron 150 micrograms kg-1
Number of subjects: 216

Group type: COMPARATOR
Intervention: Perphenazine 70 micrograms kg-1
Number of subjects: 216
Study: 8290195

Group type: EXPERIMENTAL
Intervention: Piperacillin (3 g every 6 hours) and Tazobactam (375 mg every 6 hours)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Clindamycin (900 mg every 8 hours) and Gentamicin (2.5-5.0 mg/kg/day in three divided doses)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 299

Group type: COMPARATOR
Intervention: Clindamycin-gentamicin
Number of subjects: 299
Study: 3187936

Group type: EXPERIMENTAL
Intervention: 135 g of canned mackerel paste (experimental group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Meat paste (control group)
Number of subjects: 82
Study: 5763957

Group type: EXPERIMENTAL
Intervention: 50 mg of phenylpropanolamine taken orally
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 100 mg of phenylpropanolamine taken orally
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 50 mg of phenylpropanolamine taken orally (in a subject taking tranylcypromine)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Proprietary cough linctus containing 50 mg of phenylpropanolamine (in a subject taking tranylcypromine)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine in free form
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of phentolamine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Slow-release form of phenylpropanolamine
Number of subjects: 3
Study: 30107789

Group type: EXPERIMENTAL
Intervention: Motion Simulation (MSim)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Motion Simulation and Whole Body Vibration (MSim + WBV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive exercise (all forms)
Number of subjects: 0
Study: 26867199

Group type: EXPERIMENTAL
Intervention: Gluten intake (5.6 g/day) for 7 days after a 3-week gluten-free diet (GFD)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 140
Study: 25711318

Group type: EXPERIMENTAL
Intervention: Immediate treatment at a CD4 cell count of 500 cells/μL or higher
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferring treatment until the CD4 cell count decreases to 350 cells/μL or until AIDS develops
Number of subjects: 0
Study: 23809257

Group type: EXPERIMENTAL
Intervention: Hybrid model of combined modified constraint induced movement therapy (mCIMT) followed by intensive bimanual training (COMBiT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distributed model of standard occupational therapy and physiotherapy care (SC)
Number of subjects: 50
Study: 21079425

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 24221
Study: 18449029

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 194

Group type: COMPARATOR
Intervention: β-lactams
Number of subjects: 194
Study: 17079587

Group type: EXPERIMENTAL
Intervention: Exercise therapy (3 one-on-one sessions per week for 8 weeks, followed by a home program for another 6 weeks)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Equal-contact exercise placebo intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study: 15514272

Group type: EXPERIMENTAL
Intervention: 10 mg/d iron supplementation for 12 months
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 11167929

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 2% carbohydrates
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isocaloric diet with 44% carbohydrates
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isocaloric diet with 85% carbohydrates
Number of subjects: 6
Study: 9919895

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 2 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Itraconazole 200 mg daily for 1 week
Number of subjects: 114
Study: 7850232

Group type: EXPERIMENTAL
Intervention: Fluorescent method using fluorophore K-35 for measuring total albumin concentration in human blood serum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocresol purple method
Number of subjects: 0
Study: 2965462

Group type: EXPERIMENTAL
Intervention: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally at months 0 and 1, followed by two booster injections at months 5 and 10
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 2 microgram doses of hepatitis B vaccine (HB-Vax) administered intradermally
Number of subjects: 92
Study: 16103322

Group type: EXPERIMENTAL
Intervention: SPF 40 labeled as 'high protection'
Number of subjects: 367

Group type: COMPARATOR
Intervention: SPF 40 labeled as 'basic protection'
Number of subjects: 367

Group type: COMPARATOR
Intervention: SPF 12 labeled as 'basic protection'
Number of subjects: 367
Study: 31586658

Group type: EXPERIMENTAL
Intervention: Colonization
Number of subjects: 9428

Group type: EXPERIMENTAL
Intervention: CAI
Number of subjects: 9428

Group type: EXPERIMENTAL
Intervention: CLABSI
Number of subjects: 9428
Study: 31461239

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg b.i.d.
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study: 28711577

Group type: EXPERIMENTAL
Intervention: Continuous SOX until progression
Number of subjects: 250

Group type: COMPARATOR
Intervention: Stop-and-go SOX reintroduction at progression
Number of subjects: 250
Study: 25239928

Group type: EXPERIMENTAL
Intervention: On-site SOPT with boosters
Number of subjects: 681

Group type: COMPARATOR
Intervention: Attention-control (crossword puzzles)
Number of subjects: 681
Study: 23666451

Group type: EXPERIMENTAL
Intervention: Combination of naloxone 0.1 mg, droperidol 2 mg, and dexamethasone 8 mg (Cm group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Naloxone 0.1 mg (Nx group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dexamethasone 8 mg (Dx group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Droperidol 1 mg (Dr group)
Number of subjects: 120
Study: 21672507

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive training (CAT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Paper-pencil cognitive training
Number of subjects: 29
Study: 19468216

Group type: EXPERIMENTAL
Intervention: Factor Seven for Acute Hemorrhagic Stroke (treatment group)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 801
Study: 16624768

Group type: EXPERIMENTAL
Intervention: Mechanical periodontal treatment combined with tetracycline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exclusive mechanical periodontal treatment
Number of subjects: 26
Study: 15470169

Group type: EXPERIMENTAL
Intervention: Low dose sufentanil (0.025 microg x kg(‐1) for the first patient and 0.1 microg x kg(‐1) for the other two patients)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg i.v.
Number of subjects: 3